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T-Acute Lymphoblastic Leukemia (T-ALL) remains a subgroup of pediatric ALL, with a lower response to standard chemotherapy.
Some recent studies established the fundamental role of epigenetic aberrations such asDNAhypermethylation, to influence patients’
outcome and response to chemotherapy. Moreover, L-asparaginase is an important chemotherapeutic agent for treatment of ALL
and resistance to this drug has been linked to ASNS expression, which can be silenced through methylation. Therefore, we tested
whether the sensitivity of T-ALL cell lines towards L-asparaginase is correlated to the epigenetic status ofASNS gene andwhether the
sensitivity can bemodified by concurrent demethylating treatment. Hence we treated different T-ALL cell lines with L-asparaginase
and correlated different responses to the treatment with ASNS expression. Then we demonstrated that the ASNS expression was
dependent on the methylation status of the promoter. Finally we showed that, despite the demethylating effect on the ASNS gene
expression, the combined treatment with the demethylating agent Decitabine could synergistically improve the L-asparaginase
sensitivity in those T-ALL cell lines characterized by hypermethylation of the ASNS gene. In conclusion, this preclinical study
identified an unexpected synergistic activity of L-asparaginase and Decitabine in the subgroup of T-ALL with low ASNS expression
due to hypermethylation of the ASNS promoter, while it did not restore sensitivity in the resistant cell lines characterized by higher
ASNS expression.
1. Introduction
T-Acute Lymphoblastic Leukemia is an aggressive hema-
tologic neoplasm which arises from the malignant trans-
formation of T-cell progenitors and accounts for about
15% of pediatric ALL. Despite the encouraging results
of modern chemotherapy ALL protocols, T-ALL remains,
also in the pediatric setting, a subgroup with the worst
prognosis [1, 2]. T-ALL can be divided into molecular
genetic subgroups which are characterized by unique gene
expression signatures and aberrant activation of specific
T-ALL transcription factor oncogenes, including MEF2C,
HOXA, TLX1, NKX2.1, TLX3, TAL1, LMO1, and LMO2,
and of oncogenic signaling cascades, including interleukin 7
receptor (IL7R), Janus kinase (JAK), signal transducer and
activator of transcription (STAT) [3], phosphatidylinositol 3-
kinase (PI3K)/Akt [4], and Ras/mitogen-extracellular signal-
regulated kinase (MEK)/extracellular signal-regulated kinase
(ERK) [5]. On the other hand, various studies have shown an
important role of epigenetic aberrations in the pathogenesis
of pediatric acute leukemia, including T-ALL, and resistance
to chemotherapy [6]. In particular, Borssen et al. recently
showed that the amount of CpG island methylation could
predict the outcome and response to standard treatment [7].
L-asparaginase (L-Asp) is an important chemothera-
peutic agent for the management of acute lymphoblastic
leukemia. Resistance to L-Asp therapy may also be linked
to high level of ASNS expression, which regulates the
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production of asparagine. Expression of cellular ASNS was
found low in B-lineage ALL and T-lineage ALL, thus explain-
ing the high sensitivity to L-Asp treatment [8, 9]. In this
regard, some studies described that the low expression of
ASNS in certain subgroups of ALL is due to the hyper-
methylation of the ASNS promoter [10]. Nevertheless, the
correlation of ASNS expression and sensitivity to L-Asp is
actually discussed and highly controversial [11, 12].
Considering the strong correlation between ALL out-
come and epigenetic aberrations such as DNA methylation,
the aim of our study was to investigate a possible role of
this epigenetic alteration in the sensitivity of T-ALL to L-
Asp and explore the efficacy of a combined treatment with
demethylating agents that could modulate the sensitivity to
L-Asp in this setting.
2. Materials and Methods
2.1. Cell Culture and Reagents. Human T-ALL cell lines,
DND41, HPB-ALL, RPMI 8402, CCRF-CEM, and Jurkat,
were grown in RPMI 1640 (Lonza), supplemented with
10% Fetal Bovine Serum (Invitrogen), 2mM L-glutamine
(GIBCO), 100U/mL penicillin, and 100 𝜇g/mL streptomycin
(GIBCO).
2.2. Treatment with L-Asparaginase and Decitabine. To test
the effects of L-Asp, cell lines were cultured for 48 h in the
presence of increasing drug concentrations from 10−5U/mL
to 102U/mL.
To explore the efficacy of a combined treatment with
demethylating agents, T-ALL cell lines were cultured and
treated with 1 𝜇M of Decitabine for 24 h. After 24 h cell lines
were treated with increasing concentrations of L-Asp (from
10−5 to 102) for 48 h. Due to high instability, Decitabine was
added every 24 h.
L-asparaginase (Erwinase) was purchased from Jazz
pharmaceutic; Decitabine instead was purchased from
Sigma-Aldrich.
2.3. Cell Viability Assay. Cell viability was determined using
the WST1 (4-[3-(4-lodophenyl)-2-(4-nitrophenyl)-2H-5-tet-
razolio]-1,3-benzene disulfonate) cell proliferation kit (Roche
Applied Science, Monza, Italy), according to manufacturer’s
instructions. Assays were performed in triplicate. Nonlin-
ear regression curve fit and IC50 analysis were calculated
using the GraphPad Prism software (San Diego, CA, USA).
Statistical analysis was performed using Student’s 𝑡-test at a
significance level of 𝑝 < 0.05 (GraphPad Prism Software).
For drug-combination experiments, a combination index
(CI) was calculated using the Compusyn software. CI values
<1 indicate synergism; CI = 1 indicates an additive effect,
whereas values > 1 indicate antagonism.
2.4. RNA Extraction and Quantitative PCR (qRT-PCR). Total
RNA was extracted by the RNeasy spin column method
(Qiagen). 1𝜇g total RNA was reversely transcribed to single-
stranded cDNA using the Transcriptor first strand cDNA
synthesis kit (Roche Diagnostics) with oligo-dT primers
(2.5 𝜇M). ASNS gene-specific primers were designed with
Primer Express 3.0 Software (Applied Biosystems, Monza,
Italy) and qRT-PCR was performed using FastStart Sybr
Green (Roche Diagnostics) on the LightCycler 480 appa-
ratus (Roche Diagnostics). DDCt method was used to
quantify gene expression levels, relative to the two house-
keeping genes GAPDH and ATP5B. Quantitative RT-PCR
primer sequences were as follows: ASNS forward (5󸀠-
3󸀠) GACAGAAGGATTGGCTGCCT, ASNS reverse (5󸀠-3󸀠)
CATCCAGAGCCTGAATGCCT, GAPDH forward (5󸀠-3󸀠)
CCAATATGATTCCACCCATGGC, GAPDH reverse (5󸀠-3󸀠)
CTTGATTTTCGAGGGATCTCGC, ATP5B Forward (5󸀠-
3󸀠) GTCTTCACAGGTCATATGGGGA, ATP5B reverse (5󸀠-
3󸀠)ATGGGTCCCACCATATAGAAGG. In order to prove the
anticorrelation between ASNS expression and sensitivity to
L-Asp, we calculated 𝑟2 coefficient with GraphPad Prism
software (San Diego, CA, USA). In the same way after 72 h
of Decitabine 1 𝜇M treatment, we analyzed the expression of
ASNS gene in the DND41 cell line.
2.5. Methylation Analysis. Genomic DNA was extracted
using the QIAamp DNA kit (Qiagen). Methylation analy-
sis was performed using the Epigentek Methylamp mod-
ification kit (Epigentek). After bisulfite modification, pro-
moter region of the ASNS gene (position, CpG: 74 range
= chr7:97871872–97872607) was amplified with specific
primers: ASNS forward primer (5󸀠-3󸀠) TTAGGGAATTAG-
GATAGAAAGGTTT, ASNS reverse primer (5󸀠-3󸀠) AAA-
CAAACCAAATTCAAAAACCTCC 3󸀠. PCR product was
purified and labeled with BigDye Terminator 1.1 (Applied
Biosystems) and sequenced on a ABI3730 instrument
(Applied Biosystems).
3. Results
3.1. T-ALL Cell Lines Displayed Different Sensitivity to L-Asp
Treatment. T-ALL cell lines were cultured with increas-
ing concentrations of L-Asp, ranging from 0,0001U/mL to
100U/mL and cell viability was measured 48 hours after
treatment.
The value of IC50 in T-ALL cell lines was between 10−2
and 10−4U/mL. In particular DND41, HPB-ALL, and RPMI
8402 were more sensitive than other T-ALL cell lines (Jurkat
and CCRF-CEM) (𝑝 = 0.004) (Figure 1).
3.2. The Level of L-Asparaginase Sensitivity Correlated with
ASNS Expression. The expression level of ASNS was evalu-
ated by qRT-PCR. The analysis of results showed a variable
expression ofASNS among T-ALL cell lines. In particular, cell
lines displaying high sensitivity to L-Asp treatment had lower
expression of theASNS gene, whereas cell lines showing lower
sensitivity to L-Asp treatment were characterized by higher
expression of ASNS gene. Therefore in T-ALL cell lines the
sensitivity to L-Asp treatment inversely correlated with the
expression level of the ASNS gene (𝑝 = 0.0003), showing
a mild positive correlation between the IC50 and the ASNS
expression, with a 𝑟2 of 0.6 (Figure 2).
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Figure 1: IC50 of L-asparaginase in T-ALL cell lines. DND41, HPB-ALL, and RPMI 8402 displayed higher sensitivity to L-Asp than other
T-ALL cell lines (𝑝 = 0.004).
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Figure 2: Expression analysis ofASNS gene in T-ALL cell lines. Cell lines that were more sensitive to L-Asp had lower expression of the ASNS
gene than other T-ALL cell lines (𝑝 = 0.0003).
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Figure 3: Example of cell lines with (a) hypermethylation of ASNS promoter and (b) cell lines without this epigenetic event.
3.3. Hypermethylation of the ASNS Promoter Correlated with
ASNS Expression. To characterize the mechanism of the
ASNS gene silencing in T-ALL cell lines, we analyzed the
methylation status of theASNS promoter. Sanger sequencing,
performed on bisulfite-modified DNA, displayed a complete
methylation of CpG islands in ASNS promoter in those
cell lines which had a low expression of ASNS (HPB-ALL,
DND41, and RPMI 8402) (Figure 3(a)). On the other hand,
Jurkat and CCRF-CEM cells did not display this epigenetic
signature and showed a completely unmethylated promoter
region (Figure 3(b)).
3.4. Decitabine Improved L-Asp Sensitivity in Cell Lines with
Hypermethylation of ASNS CpG Islands. To better correlate
the ASNS expression level with promoter methylation and
check the effect of a demethylating agent to modulate L-Asp
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Figure 4: Synergic effect of Decitabine and L-Asp in RPMI 8402, DND41, and HPB-ALL. At 10−4 and 10−5 U/mL L-Asp alone did not affect
cell viability, but addition of 1𝜇M of Decitabine displayed a statistically significant synergic effect (∗∗∗𝑝 value <0.001). CI values <1 indicates
synergism; CI = 1 indicates additive effect, whereas values > 1 indicates antagonism.
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Figure 5: Jurkat and CCRF-CEM did not display synergism between Decitabine and L-asparaginase. CI values <1 indicate synergism; CI = 1
indicates additive effect, whereas values > 1 indicate antagonism.
sensitivity, we treated all T-ALL cell lines with Decitabine
1 𝜇M, in combination with increasing concentrations of L-
Asp. Analysis of the results showed a reproducible toxicity
in all T-ALL cell lines with about 50% of inhibition of cell
viability. Unexpectedly, in cell lines displaying hypermethy-
lation of ASNS promoter, Decitabine and L-Asp exhibited a
strong synergistic effect with a value of combination index
(CI)< 1 (Figure 4). In particular, concentrations of 10−4U/mL
and 10−5U/mL of L-Asp alone did not affect cell viability,
but the percentage of citotoxicity increased dramatically in
association with Decitabine. Other cell lines (Jurkat and
CCRF-CEM) without methylation of ASNS promoter did
not display this combined effect (CI > 1) (Figure 5). To
confirm the reactivation of ASNS expression after Decitabine
treatment, we performed qPCR of ASNS gene in DND41 cell
line. Following 72 h of treatment with 1 𝜇MofDecitabine, our
data showed a significant increase in expression of the ASNS
gene (𝑝 < 0.001) (Figure 6).
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Figure 6: Expression of the ASNS gene in DND41 cell line after 72 h
of treatment with 1 𝜇M of Decitabine. (∗∗∗𝑝 value <0.001).
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4. Discussion and Conclusion
T-ALL originates from T-cell precursors at different stages of
their development and is characterized by distinct and well
characterized molecular genetic subtypes. Children affected
by this disease respond fairly well to high-dose chemotherapy
regimens [1]. L-asparaginase is an important chemothera-
peutic agent for the management of acute lymphoblastic
leukemia. Resistance to L-Asp therapy may also be linked
to high levels of ASNS cellular expression, which allows
the production of asparagine. Expression of cellular ASNS
is low in B-lineage ALL, explaining the higher sensitivity
to L-Asp treatment. One mechanism implicated in gene
silencing of ASNS is hypermethylation of the ASNS pro-
moter. Moreover, in the last years some studies highlighted
that epigenetic aberration may be determinant in inducing
resistance to chemotherapy and poor outcome in T-ALL.
Treatment with demethylating agents looks promising in an
effort to provide new treatment options in T-cell malig-
nant disorders [13]. In this context, our study attempted to
investigate an epigenetic marker that could correlate with
a high sensitivity to L-Asp and explored the interaction
with demethylating agents such as Decitabine. Therefore we
treated T-ALL cell lines with increasing concentrations of L-
Asp and found a subgroup of T-ALL cell lines displaying a
high sensitivity to treatment. Then we confirmed that cell
lines showing high sensitivity to L-Asp treatment had a very
low expression of ASNS gene, which is in line with some
literature data [10]. In our study, the mechanism of gene
silencing in T-ALL cell lines displaying low expression of
ASNS gene appeared to be linked to hypermethylation of
the ASNS promoter as already shown [10]. Unexpectedly, we
found a strong synergic effect of L-ASP and Decitabine, a
demethylating agent, in cell lines with hypermethylation of
ASNS at base line evaluation, DND41, HPB-ALL, and RPMI
8402.
This result seems to underline a different role of hyper-
methylation of ASNS promoter in the cellular response to
L-Asp.
Therefore other studies are necessary to further explain
the molecular mechanism underlying this result, which is
probably linked to a larger set of methylated genes in T-
ALL subset. In particular, methylation status may not be
restricted to ASNS gene and the reactivation of many genes
such as oncosuppressors could have an important role in
the synergic cytotoxic effect induced by Decitabine. The
clinical translation of these data is not immediately pre-
dictable; however it remains an intriguing result because
of the fact that cotreatment with a demethylating agent as
Decitabine results in a synergistic effect.The role of demethy-
lating agents in combination with standard chemother-
apy should be further analyzed in preclinical and ex vivo
models.
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